Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody Therapy
COLUMBUS, Ohio – June 1, 2023 – Clarametyx Biosciences, Inc. (“Clarametyx”), a…
Clarametyx Biosciences Announces Changes to Its Scientific Advisory Board
Renowned vaccine R&D expert Dr. Jeffrey Almond joins to advise on…